Ligand Pharmaceuticals Incorporated (LGND) Insider Trading
- $5,339,328.39
- $218,162,557.55
- Sept. 23, 2024
- John L Higgins
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| March 20, 2017 | CEO | 4,000 | $109.10 | Sell | $436,400.00 | |
| March 2, 2017 | Insider | 6,879 | $103.39 | Sell | $711,219.81 | |
| Feb. 28, 2017 | Director | 32,000 | $106.35 | Sell | $3,403,200.00 | |
| Nov. 25, 2016 | Director | 18,479 | $107.31 | Sell | $1,982,981.49 | |
| Nov. 18, 2016 | Director | 6,330 | $105.28 | Sell | $666,422.40 | |
| Sept. 22, 2016 | CEO | 3,000 | $117.34 | Sell | $352,020.00 | |
| Sept. 7, 2016 | Director | 1,000 | $115.00 | Sell | $115,000.00 | |
| Sept. 1, 2016 | Director | 1,666 | $105.40 | Sell | $175,596.40 | |
| Aug. 1, 2016 | Director | 1,000 | $137.57 | Sell | $137,570.00 | |
| July 1, 2016 | Director | 1,000 | $121.40 | Sell | $121,400.00 | |
| June 1, 2016 | Director | 1,000 | $117.42 | Sell | $117,420.00 | |
| May 18, 2016 | Director | 334 | $120.50 | Sell | $40,247.00 | |
| May 6, 2016 | Director | 25,000 | $119.20 | Sell | $2,980,000.00 | |
| May 2, 2016 | Director | 1,000 | $121.57 | Sell | $121,570.00 | |
| April 6, 2016 | Director | 5,000 | $115.00 | Sell | $575,000.00 | |
| March 17, 2016 | COO | 6,400 | $96.70 | Sell | $618,880.00 | |
| March 8, 2016 | Director | 6,129 | $101.18 | Sell | $620,132.22 | |
| March 7, 2016 | CEO | 10,833 | $102.47 | Sell | $1,110,057.51 | |
| Jan. 20, 2016 | Director | 1,666 | $94.94 | Sell | $158,170.04 | |
| Nov. 11, 2015 | Director | 7,719 | $101.00 | Sell | $779,619.00 | |
| Aug. 17, 2015 | Director | 4,000 | $95.98 | Sell | $383,920.00 | |
| Aug. 13, 2015 | Director | 49,800 | $96.26 | Sell | $4,793,748.00 | |
| July 10, 2015 | VP | 14,067 | $99.14 | Sell | $1,394,602.38 | |
| June 26, 2015 | COO | 12,500 | $100.97 | Sell | $1,262,125.00 | |
| June 22, 2015 | COO | 23,046 | $96.45 | Sell | $2,222,786.70 | |
| June 10, 2015 | CFO | 4,125 | $93.50 | Sell | $385,687.50 | |
| June 9, 2015 | CEO | 10,000 | $92.88 | Sell | $928,800.00 | |
| June 4, 2015 | Director | 1,640 | $92.68 | Sell | $151,995.20 | |
| May 20, 2015 | Director | 9,240 | $87.34 | Sell | $807,021.60 | |
| May 14, 2015 | CFO | 68,363 | $83.91 | Sell | $5,736,339.33 | |
| March 19, 2015 | Director | 4,591 | $74.42 | Sell | $341,662.22 | |
| Feb. 10, 2015 | VP | 2,300 | $56.34 | Sell | $129,582.00 | |
| Oct. 15, 2014 | Director | 2,000 | $45.68 | Buy | $91,360.00 | |
| Oct. 9, 2014 | Director | 11,000 | $42.99 | Buy | $472,890.00 | |
| Aug. 15, 2014 | CEO | 1,000 | $54.97 | Buy | $54,970.00 | |
| June 9, 2014 | Director | 1,100 | $69.68 | Sell | $76,648.00 | |
| May 27, 2014 | VP | 7,166 | $66.90 | Sell | $479,405.40 | |
| March 25, 2014 | Insider | 78,226 | $70.09 | Sell | $5,482,860.34 | |
| March 19, 2014 | Director | 7,500 | $79.57 | Sell | $596,775.00 | |
| March 18, 2014 | Director | 5,000 | $78.83 | Sell | $394,150.00 | |
| Feb. 20, 2014 | major shareholder | 422,900 | $73.81 | Sell | $31,214,249.00 | |
| Feb. 18, 2014 | Director | 41,900 | $75.71 | Sell | $3,172,249.00 | |
| Feb. 14, 2014 | Director | 40,320 | $76.44 | Sell | $3,082,060.80 | |
| Feb. 14, 2014 | COO | 22,500 | $79.54 | Sell | $1,789,650.00 | |
| Dec. 12, 2013 | COO | 6,000 | $53.40 | Sell | $320,400.00 | |
| Dec. 6, 2013 | CFO | 6,000 | $56.08 | Sell | $336,480.00 | |
| Oct. 18, 2013 | CEO | 10,000 | $55.00 | Sell | $550,000.00 | |
| Sept. 23, 2013 | major shareholder | 359,023 | $44.50 | Sell | $15,976,523.50 | |
| Sept. 12, 2013 | Director | 160,000 | $46.78 | Sell | $7,484,800.00 | |
| Aug. 30, 2013 | VP | 28,323 | $47.54 | Sell | $1,346,475.42 |
Insiders are both buying and selling Ligand Pharmaceuticals Incorporated stock.
The insider traders at Ligand Pharmaceuticals Incorporated are: Matthew W Foehr, John L Higgins, Jason Aryeh, John W Kozarich, Charles S Berkman, Matthew E Korenberg, Todd C Davis, Octavio Espinoza, Andrew Reardon, Bvf Partners L P/Il, Stephen L Sabba, John L Lamattina, David M Knott, Melanie J Herman, Bvf Partners P/Il, Sunil Patel, Matthew Foehr, David Knott, Nishan M Desilva, Charles Berkman, John Sharp, John Higgins, Todd Davis, John Lamattina, Melanie J. Herman, and John W. Kozarich
The most active insider trader at Ligand Pharmaceuticals Incorporated is Matthew W Foehr with 27 trades.
Bvf Partners P/Il has sold the most Ligand Pharmaceuticals Incorporated stock with a total value of $58,156,493.18.
Bvf Partners L P/Il has bought the most Ligand Pharmaceuticals Incorporated stock with a total value of $2,817,728.47.
The most recent insider trade for Ligand Pharmaceuticals Incorporated was on Sept. 23, 2024.
The single biggest insider buy for Ligand Pharmaceuticals Incorporated was from Bvf Partners L P/Il with a total value of $898,794.00 on Dec. 6, 2012.
The single biggest insider sell for Ligand Pharmaceuticals Incorporated was from Bvf Partners P/Il with a total value of $31,214,249.00 on Feb. 20, 2014.